Cibus Reports Q1 2025 Results & Expands Gene Editing Pipeline
Cibus reported a net loss of $49.4M for Q1 2025, mainly due to a $21M goodwill impairment, they also reported updates in regulatory decisions.
Cibus reported a net loss of $49.4M for Q1 2025, mainly due to a $21M goodwill impairment, they also reported updates in regulatory decisions.
genXtraits partners with Solis Agrosciences to create & commercialize novel crop varieties or license them to seed companies.
To provide the best experience, we use technologies like cookies to store and access device information.